Meeting
2019 ASCO Annual Meeting
Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance).
Authors
Noam Falbel Ponde
AC Camargo Cancer Center, São Paulo, Brazil
Noam Falbel Ponde , Dominique Agbor-Tarh , Lissandra Dal Lago , Larissa A. Korde , Florentine Hilbers , Christian Jackisch , Olena Werner , Richard D. Gelber , Aminah Jatoi , Amylou C. Dueck , Alvaro Moreno-Aspitia , Christos Sotiriou , Evandro de Azambuja , Martine Piccart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Geriatric Models of Care
Citation
J Clin Oncol 37, 2019 (suppl; abstr 11553)
DOI
10.1200/JCO.2019.37.15_suppl.11553
Abstract #
11553
Poster Bd #
245
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association of polypharmacy and potential drug-drug interactions with adverse outcomes in older adults with advanced cancer receiving systemic treatment.
First Author: Mostafa Refaat Mohamed
Poster
2020 ASCO Virtual Scientific Program
External validation of two predictive scores of chemotherapy toxicities among older patients with solid cancer, from ELCAPA prospective cohort.
First Author: Maxime Frelaut
Poster
2017 ASCO Annual Meeting
Polypharmacy and potentially inappropriate medication use in older patients with aggressive non-Hodgkin lymphoma (NHL) leads to inferior survival and increased treatment-related toxicities.
First Author: Richard Jirui Lin
Poster
2016 Palliative and Supportive Care in Oncology Symposium
Contribution of polypharmacy and potentially inappropriate medication use to inferior survival in older patients with aggressive lymphoma.
First Author: Richard Jirui Lin